Suppr超能文献

甲状腺乳头状癌中TROP-2的表达:一项初步细胞-组织学研究。

TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study.

作者信息

Addati T, Achille G, Centrone M, Petroni S, Popescu O, Russo S, Grammatica L, Simone G

机构信息

Anatomic Pathology Unit, National Cancer Research Centre Istituto Tumori 'Giovanni Paolo II', Bari, Italy.

Otorhinolaryngology Unit, National Cancer Research Centre Istituto Tumori 'Giovanni Paolo II', Bari, Italy.

出版信息

Cytopathology. 2015 Oct;26(5):303-11. doi: 10.1111/cyt.12196. Epub 2014 Aug 27.

Abstract

OBJECTIVE

TROP-2 (human trophoblast cell surface marker) is a gene-related protein expressed in trophoblastic cells, which is also present in a variety of epithelial cancers and whose overexpression has been found to correlate with a poor prognosis. We analysed the possibility of using the expression of TROP-2 to detect papillary thyroid carcinoma (PTC) on cytological and histological samples, and compared it with Hector Battifora mesothelial antigen-1 (HBME-1).

METHODS

From 127 patients, 127 fine needle aspirates (FNAs), in which HBME-1 was detected by immunocytochemistry (ICC), were re-classified according to the Bethesda system for reporting thyroid cytopathology (TBSRTC): 20% were benign, 56% were atypical cells/follicular lesion of undetermined significance (AUS/FLUS), 4% were follicular neoplasm/suspicious for a follicular neoplasm, 5% were suspicious for malignancy and 16% were malignant. Sufficient material to test for TROP-2 was available in 64 FNAs, 22 of which had a histological control. Including six additional cases in which the FNAs were not available, immunohistochemistry (IHC) was carried out with both markers on 94 cases.

RESULTS

Among 88 FNAs with histological control, the sensitivity of HBME-1 to predict PTC was 87.5% (28/32) and the specificity was 86% (48/56), whereas, in 22 FNAs, TROP-2 sensitivity was 100% (13/13) and specificity was 89% (8/9). In 94 histological specimens in which IHC was carried out with both markers, the sensitivity and specificity were 82% and 86%, respectively, for HBME-1 and 87% and 89%, respectively, for TROP-2. The difference between the markers was not significant. Concordance between IHC and ICC was 76% for HBME-1 and 91% for TROP-2.

CONCLUSION

TROP-2 can be used as well as HBME-1 in thyroid cytology to detect PTC. Positivity for either or both markers could help to stratify the risk of malignancy in indeterminate FNAs. Larger studies are need to analyse its role in the behaviour of PTC and its variants.

摘要

目的

TROP-2(人滋养层细胞表面标志物)是一种在滋养层细胞中表达的基因相关蛋白,也存在于多种上皮癌中,且其过表达与预后不良相关。我们分析了利用TROP-2的表达在细胞学和组织学样本上检测甲状腺乳头状癌(PTC)的可能性,并将其与赫克托·巴蒂福拉间皮抗原-1(HBME-1)进行比较。

方法

从127例患者中获取了127份细针穿刺抽吸物(FNA),通过免疫细胞化学(ICC)检测其中的HBME-1,并根据甲状腺细胞病理学报告的贝塞斯达系统(TBSRTC)重新分类:20%为良性,56%为非典型细胞/意义未明的滤泡性病变(AUS/FLUS),4%为滤泡性肿瘤/可疑滤泡性肿瘤,5%为可疑恶性,16%为恶性。64份FNA中有足够的材料用于检测TROP-2,其中22份有组织学对照。包括另外6例没有FNA的病例,对94例病例同时使用这两种标志物进行了免疫组织化学(IHC)检测。

结果

在88份有组织学对照的FNA中,HBME-1预测PTC的敏感性为87.5%(28/32),特异性为86%(48/56),而在22份FNA中,TROP-2的敏感性为100%(13/13),特异性为89%(8/9)。在94份同时使用这两种标志物进行IHC检测的组织学标本中,HBME-1的敏感性和特异性分别为82%和86%,TROP-这两种标志物之间的差异不显著。HBME-1的IHC和ICC之间的一致性为76%,TROP-2为91%。

结论

在甲状腺细胞学中,TROP-2与HBME-1一样可用于检测PTC。一种或两种标志物呈阳性有助于对不确定FNA的恶性风险进行分层。需要进行更大规模的研究来分析其在PTC及其变体行为中的作用。 2的敏感性和特异性分别为87%和89%。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验